EMA committee recommends approval of Vertex's Kaftrio in combo with ivacaftor in children with CF ages 6 through 11 years old

Vertex Pharmaceuticals Incorporated, a global biotechnology company, announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the label extension [...]